About two years ago, Cerberus Capital Management agreed to buyout Talecris Biotherapeutics. So far, it looks like a winner. In 2006, Talecris paid a $760 million dividend. Oh, and now the company has filed to go public.
Talecris is one of the largest producers and marketers of plasma-derived protein therapies. These therapies help to extend the lives of people who suffer from immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns.
Last year, the company posted revenues of $1.1 billion and net income of $87.4 million. Adjusted EBITDA was $264.1 million.
The roots of Talecris go back to the early 1940s and eventually became part of Bayer Healthcare (NYSE: BAY).
The underwriters on the IPO include Morgan Stanley (NYSE: MS), Goldman Sachs (NYSE: GS), and JPMorgan (NYSE: JPM). The proposed ticker symbol is "TLCR."
You can find the prospectus at the SEC website. Also, if you want to check out more recent IPO filings, click here.
Tom Taulli is the author of various books, including the Complete M&A Handbook and the EDGAR-Online Guide to Decoding Financial Statements.
Closing Bell: Dubai sends jitters throughout the market (S, BBY)
Heinz looking good after the second quarter?
Why isn't Bank of America updating its shareholders on CEO situation?
